SCHEMBL12875552

SCHEMBL12875552

COc1ccccc1-c1csc(-n2ncc(C(=O)O)c2C)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
SIRT5 Q9NXA8 2/20 0.50
MEN1 O00255 4/20 0.49
ATM Q13315 1/20 0.49
HPGDS O60760 1/20 0.48
KDM4E B2RXH2 4/20 0.48
HPGD P15428 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
PTGER4 P35408 1/20 0.48
EIF4E P06730 2/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP19A1 P11511 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875551 0.88 HPGD (0.61) KMT2ARAB9ANPC1SIRT5MEN1
SCHEMBL12875575 0.87 PTGER1 (0.47) KMT2ARAB9ANPC1MEN1ATM
SCHEMBL14224567 0.86 PTGER4 (0.51) KMT2ARAB9ANPC1SIRT5MEN1
SCHEMBL1199230 0.85 KMT2A (0.69) KMT2ARAB9ANPC1SIRT5MEN1
SCHEMBL12875565 0.84 KDM4E (0.45) KMT2ARAB9ANPC1SIRT5MEN1
SCHEMBL12875465 0.83 RAB9A (0.63) KMT2ARAB9ANPC1MEN1ATM
SCHEMBL4827453 0.82 KDM4E (0.54) KMT2ARAB9ANPC1MEN1ATM
SCHEMBL14196468 0.81 RAB9A (0.60) KMT2ARAB9ANPC1MEN1ATM
SCHEMBL14196464 0.79 MEN1 (0.57) KMT2ARAB9ANPC1SIRT5MEN1
SCHEMBL12875570 0.78 HPGD (0.56) KMT2ARAB9ANPC1MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KMT2A 3197/4885RAB9A 2507/4885NPC1 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.